# Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

> **NCT07236476** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Assisted Reproduction

## Interventions

- **DRUG:** LY01021

## Key facts

- **NCT ID:** NCT07236476
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07236476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07236476, "Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07236476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*